RARE DISEASE COMPANY COALITION — Lobbying Disclosure | Poliscope

RARE DISEASE COMPANY COALITION

View full entity profile (contributions, contracts, SEC) →

This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.

Lobbying Spend

$550K

Filings

Firms Hired

Active Period

2021–2026

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2026	$260,000	6	2
2025	$290,000	11	3
2024	—	4	1
2023	—	4	1
2022	—	4	1
2021	—	5	1

Hired Firms

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
RARE DISEASE COMPANY COALITION	$550,000	8
THE KPM GROUP DC LLC	—	17
FEROX STRATEGIES	—	7
LMH STRATEGIC SOLUTIONS	—	2

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	29
SENATE	29
Health & Human Services, Dept of (HHS)	6
Commerce, Dept of (DOC)	5
Executive Office of the President (EOP)	4
Natl Institutes of Health (NIH)	3
Food & Drug Administration (FDA)	2
Office of Management & Budget (OMB)	2
Centers For Medicare and Medicaid Services (CMS)	1
U.S. Trade Representative (USTR)	1
White House Office	1

Top Issues

Most frequently reported lobbying issues

Issue Code	Description	Reports
Pharmacy	Pharmacy	24
Health Issues	Health Issues	15
Trade (domestic/foreign)	Trade (domestic/foreign)	9
Taxation/Internal Revenue Code	Taxation/Internal Revenue Code	8
Science/Technology	Science/Technology	4
Medicare/Medicaid	Medicare/Medicaid	3
Budget/Appropriations	Budget/Appropriations	2

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 10359119th Congress

Priority for Pediatric Cures Act

2026 · third_quarter · Firm: RARE DISEASE COMPANY COALITION

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 10359 - Priority Review Voucher (PRV) permanence bill H.R. 1532/S. 822 - Scientific EXPERT Act 42 CFR Part 513 - Rare disease exemption from GLOBE mode/final rule 91 FR 18183 - Clarification of orphan exemption from 232 pharmaceutical tariffs H.R. 1414 - Orphan Drug Tax Credit

Client expense: $80,000 · Firm income: —

Matched citations: H.R. 10359

H.R. 1414119th Congress

Cameron’s Law

2026 · third_quarter · Firm: RARE DISEASE COMPANY COALITION

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 10359 - Priority Review Voucher (PRV) permanence bill H.R. 1532/S. 822 - Scientific EXPERT Act 42 CFR Part 513 - Rare disease exemption from GLOBE mode/final rule 91 FR 18183 - Clarification of orphan exemption from 232 pharmaceutical tariffs H.R. 1414 - Orphan Drug Tax Credit

Client expense: $80,000 · Firm income: —

Matched citations: H.R. 1414

H.R. 1532119th Congress

Scientific EXPERT Act of 2025

2026 · third_quarter · Firm: RARE DISEASE COMPANY COALITION

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 10359 - Priority Review Voucher (PRV) permanence bill H.R. 1532/S. 822 - Scientific EXPERT Act 42 CFR Part 513 - Rare disease exemption from GLOBE mode/final rule 91 FR 18183 - Clarification of orphan exemption from 232 pharmaceutical tariffs H.R. 1414 - Orphan Drug Tax Credit

Client expense: $80,000 · Firm income: —

Matched citations: H.R. 1532

S. 822119th Congress

Scientific EXPERT Act of 2025

2026 · third_quarter · Firm: RARE DISEASE COMPANY COALITION

Open original LDA filing ↗

Cited source text and reported amounts

H.R. 10359 - Priority Review Voucher (PRV) permanence bill H.R. 1532/S. 822 - Scientific EXPERT Act 42 CFR Part 513 - Rare disease exemption from GLOBE mode/final rule 91 FR 18183 - Clarification of orphan exemption from 232 pharmaceutical tariffs H.R. 1414 - Orphan Drug Tax Credit

Client expense: $80,000 · Firm income: —

Matched citations: S. 822

Show 21 more cited filings

H.R. 1119th Congress

An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

2026 · second_quarter · Firm: RARE DISEASE COMPANY COALITION

Open original LDA filing ↗

Cited source text and reported amounts

HR 1 / Public Law - ORPHAN Cures Act HR 1414 - Camerons Law HR 7148 / Public Law 119-75 - PRV Reauthorization CMS-5545-P - Global Benchmark for Efficient Drug Pricing (GLOBE) CMS-5546-P - Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Proclamation 11020 - Exemption for Orphan Drugs from 232 Pharmaceutical Tariffs Rare Disease Innovation Issues

Client expense: $70,000 · Firm income: —

Matched citations: HR 1

H.R. 1414119th Congress

Cameron’s Law

2026 · second_quarter · Firm: RARE DISEASE COMPANY COALITION

Open original LDA filing ↗

Cited source text and reported amounts

HR 1 / Public Law - ORPHAN Cures Act HR 1414 - Camerons Law HR 7148 / Public Law 119-75 - PRV Reauthorization CMS-5545-P - Global Benchmark for Efficient Drug Pricing (GLOBE) CMS-5546-P - Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Proclamation 11020 - Exemption for Orphan Drugs from 232 Pharmaceutical Tariffs Rare Disease Innovation Issues

Client expense: $70,000 · Firm income: —

Matched citations: HR 1414

H.R. 7148119th Congress

Consolidated Appropriations Act, 2026

2026 · second_quarter · Firm: RARE DISEASE COMPANY COALITION

Open original LDA filing ↗

Cited source text and reported amounts

HR 1 / Public Law - ORPHAN Cures Act HR 1414 - Camerons Law HR 7148 / Public Law 119-75 - PRV Reauthorization CMS-5545-P - Global Benchmark for Efficient Drug Pricing (GLOBE) CMS-5546-P - Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Proclamation 11020 - Exemption for Orphan Drugs from 232 Pharmaceutical Tariffs Rare Disease Innovation Issues

Client expense: $70,000 · Firm income: —

Matched citations: HR 7148

H.R. 1262119th Congress

Mikaela Naylon Give Kids a Chance Act

2026 · first_quarter · Firm: RARE DISEASE COMPANY COALITION

Open original LDA filing ↗

Cited source text and reported amounts

HR 1262 - Give Kids a Chance Act of 2025 S 3302/S 932 - Give Kids a Chance Act of 2025 HR 1762 - Lower Costs for Every Day Americans Act 42 CFR Part 513/514 - Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Models EO 14297 - Exemption for Orphan Drugs from MFN Proposals

Client expense: $110,000 · Firm income: —

Matched citations: HR 1262

H.R. 1762119th Congress

Forest Service Accountability Act

2026 · first_quarter · Firm: RARE DISEASE COMPANY COALITION

Open original LDA filing ↗

Cited source text and reported amounts

HR 1262 - Give Kids a Chance Act of 2025 S 3302/S 932 - Give Kids a Chance Act of 2025 HR 1762 - Lower Costs for Every Day Americans Act 42 CFR Part 513/514 - Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Models EO 14297 - Exemption for Orphan Drugs from MFN Proposals

Client expense: $110,000 · Firm income: —

Matched citations: HR 1762

S. 3302119th Congress

Mikaela Naylon Give Kids a Chance Act of 2025

2026 · first_quarter · Firm: RARE DISEASE COMPANY COALITION

Open original LDA filing ↗

Cited source text and reported amounts

HR 1262 - Give Kids a Chance Act of 2025 S 3302/S 932 - Give Kids a Chance Act of 2025 HR 1762 - Lower Costs for Every Day Americans Act 42 CFR Part 513/514 - Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Models EO 14297 - Exemption for Orphan Drugs from MFN Proposals

Client expense: $110,000 · Firm income: —

Matched citations: S 3302

S. 932119th Congress

Give Kids a Chance Act of 2025

2026 · first_quarter · Firm: RARE DISEASE COMPANY COALITION

Open original LDA filing ↗

Cited source text and reported amounts

HR 1262 - Give Kids a Chance Act of 2025 S 3302/S 932 - Give Kids a Chance Act of 2025 HR 1762 - Lower Costs for Every Day Americans Act 42 CFR Part 513/514 - Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Models EO 14297 - Exemption for Orphan Drugs from MFN Proposals

Client expense: $110,000 · Firm income: —

Matched citations: S 932

H.R. 1262119th Congress

Mikaela Naylon Give Kids a Chance Act

2025 · fourth_quarter · Firm: RARE DISEASE COMPANY COALITION

Open original LDA filing ↗

Cited source text and reported amounts

HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 Rare Disease Exemption for Most Favored Nation Pricing Proposals

Client expense: $70,000 · Firm income: —

Matched citations: HR 1262

S. 932119th Congress

Give Kids a Chance Act of 2025

2025 · fourth_quarter · Firm: RARE DISEASE COMPANY COALITION

Open original LDA filing ↗

Cited source text and reported amounts

HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 Rare Disease Exemption for Most Favored Nation Pricing Proposals

Client expense: $70,000 · Firm income: —

Matched citations: S 932

H.R. 1119th Congress

An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

2025 · third_quarter · Firm: RARE DISEASE COMPANY COALITION

Open original LDA filing ↗

Cited source text and reported amounts

HR 1 - Big Beautiful Bill Act

Client expense: $90,000 · Firm income: —

Matched citations: HR 1

H.R. 1262119th Congress

Mikaela Naylon Give Kids a Chance Act

2025 · third_quarter · Firm: RARE DISEASE COMPANY COALITION

Open original LDA filing ↗

Cited source text and reported amounts

HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law Drug Pricing EO 14297: Most Favored Nation Pricing Proposals

Client expense: $90,000 · Firm income: —

Matched citations: HR 1262

H.R. 1414119th Congress

Cameron’s Law

2025 · third_quarter · Firm: RARE DISEASE COMPANY COALITION

Open original LDA filing ↗

Cited source text and reported amounts

HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law Drug Pricing EO 14297: Most Favored Nation Pricing Proposals

Client expense: $90,000 · Firm income: —

Matched citations: HR 1414

H.R. 946119th Congress

ORPHAN Cures Act

2025 · third_quarter · Firm: RARE DISEASE COMPANY COALITION

Open original LDA filing ↗

Cited source text and reported amounts

HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law Drug Pricing EO 14297: Most Favored Nation Pricing Proposals

Client expense: $90,000 · Firm income: —

Matched citations: HR 946

S. 1862119th Congress

ORPHAN Cures Act

2025 · third_quarter · Firm: RARE DISEASE COMPANY COALITION

Open original LDA filing ↗

Cited source text and reported amounts

HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law Drug Pricing EO 14297: Most Favored Nation Pricing Proposals

Client expense: $90,000 · Firm income: —

Matched citations: S 1862

S. 932119th Congress

Give Kids a Chance Act of 2025

2025 · third_quarter · Firm: RARE DISEASE COMPANY COALITION

Open original LDA filing ↗

Cited source text and reported amounts

HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law Drug Pricing EO 14297: Most Favored Nation Pricing Proposals

Client expense: $90,000 · Firm income: —

Matched citations: S 932

H.R. 1119th Congress

An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

2025 · second_quarter · Firm: RARE DISEASE COMPANY COALITION

Open original LDA filing ↗

Cited source text and reported amounts

HR 1 - Big Beautiful Bill Act

Client expense: $70,000 · Firm income: —

Matched citations: HR 1

H.R. 1262119th Congress

Mikaela Naylon Give Kids a Chance Act

2025 · second_quarter · Firm: RARE DISEASE COMPANY COALITION

Open original LDA filing ↗

Cited source text and reported amounts

HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law FDA Regulatory Priorities

Client expense: $70,000 · Firm income: —

Matched citations: HR 1262

H.R. 1414119th Congress

Cameron’s Law

2025 · second_quarter · Firm: RARE DISEASE COMPANY COALITION

Open original LDA filing ↗

Cited source text and reported amounts

HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law FDA Regulatory Priorities

Client expense: $70,000 · Firm income: —

Matched citations: HR 1414

H.R. 946119th Congress

ORPHAN Cures Act

2025 · second_quarter · Firm: RARE DISEASE COMPANY COALITION

Open original LDA filing ↗

Cited source text and reported amounts

HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law FDA Regulatory Priorities

Client expense: $70,000 · Firm income: —

Matched citations: HR 946

S. 1862119th Congress

ORPHAN Cures Act

2025 · second_quarter · Firm: RARE DISEASE COMPANY COALITION

Open original LDA filing ↗

Cited source text and reported amounts

HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law FDA Regulatory Priorities

Client expense: $70,000 · Firm income: —

Matched citations: S 1862

S. 932119th Congress

Give Kids a Chance Act of 2025

2025 · second_quarter · Firm: RARE DISEASE COMPANY COALITION

Open original LDA filing ↗

Cited source text and reported amounts

HR 1262 - Give Kids a Chance Act of 2025 S 932 - Give Kids a Chance Act of 2025 HR 946 - ORPHAN Cures Act S 1862 - ORPHAN Cures Act HR 1414 - Camerons Law FDA Regulatory Priorities

Client expense: $70,000 · Firm income: —

Matched citations: S 932

Source: Senate LDA